Compass Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Compass Therapeutics, Inc. - overview
Established
2014
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Founded in 2014 by CEO Thomas Schuetz and CSO Piotr Bobrowicz and based in Massachusetts, US, Compass Therapeutics, Inc. is a biotechnology company that focuses on the development of therapeutic antibodies for the treatment of cancer and other tumor-immune synapses. In June 2020, Compass Therapeutics LLC raised USD 60 million in PIPE funding from Consonance Capital Partners and Limulus Venture Partners. Biomatics Capital Partners, BioMed Ventures, Borealis Ventures, and other investors also participated in the round.
In June 2020, after the merger with Olivia Ventures, Inc. , Compass Therapeutics, Inc. will operate as a public company. In November 2021, Compass Therapeutics, Inc.
raised USD 125 million in a private placement, selling 35. 72 million shares at USD 3. 50 per share on the NASDAQ. It trades on NASDAQ under the ticker symbol CMPX.
In May 2021, Compass Therapeutics, Inc. acquired TRIGR Therapeutics, Inc. , a private biotechnology oncology company, in a stock for stock transaction. The products in the company's pipeline include CTX-009, CTX-471, CTX-8371.
CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). CTX-009 has completed Phase 1 dose-escalation and expansion study, and a Phase 1b in combination with chemotherapy is ongoing. CTX-009 has shown clinical efficacy as a monotherapy in severely pre-treated patients who have progressed following prior VEGF, EGFR, HER2, and PD1/L1-targeted treatments. CTX-471 is a fully human agonistic antibody of CD137.
CTX-471 is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. CTX-8371 is a bispecific antibody that targets both the programmed death receptor (PD-1) and the programmed death ligand-receptor (PD-L1) on immune and cancer cells, respectively. CTX-8371 is currently undergoing IND-enabling preclinical development. Compass Therapeutics, Inc.
plans to use the PIPE funding for the advancement of its antibody-based therapeutics into clinics.
Current Investors
F-Prime Capital, Borealis, Alumni Ventures Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.compasstherapeutics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Compass Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | - | (32,759) | (32,105) | (25,408,000) | (81,316,000) | (41,674,000) | - | - | - |
| Operating Income (USD) | - | (32,759) | (32,105) | (27,812,000) | (81,882,000) | (41,655,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | - | (36,037) | (37,483) | (29,500,000) | (82,181,000) | (39,225,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - |
Compass Therapeutics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.